<!DOCTYPE html>
<html>

<head>

<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">
<title>Clinical Practice - Stroke</title>


<style type="text/css">
body {
  font-family: Helvetica, arial, sans-serif;
  font-size: 14px;
  line-height: 1.6;
  padding-top: 10px;
  padding-bottom: 10px;
  background-color: white;
  padding: 30px; }

body > *:first-child {
  margin-top: 0 !important; }
body > *:last-child {
  margin-bottom: 0 !important; }

a {
  color: #4183C4; }
a.absent {
  color: #cc0000; }
a.anchor {
  display: block;
  padding-left: 30px;
  margin-left: -30px;
  cursor: pointer;
  position: absolute;
  top: 0;
  left: 0;
  bottom: 0; }

h1, h2, h3, h4, h5, h6 {
  margin: 20px 0 10px;
  padding: 0;
  font-weight: bold;
  -webkit-font-smoothing: antialiased;
  cursor: text;
  position: relative; }

h1:hover a.anchor, h2:hover a.anchor, h3:hover a.anchor, h4:hover a.anchor, h5:hover a.anchor, h6:hover a.anchor {
  background: url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABAAAAAQCAYAAAAf8/9hAAAAGXRFWHRTb2Z0d2FyZQBBZG9iZSBJbWFnZVJlYWR5ccllPAAAA09pVFh0WE1MOmNvbS5hZG9iZS54bXAAAAAAADw/eHBhY2tldCBiZWdpbj0i77u/IiBpZD0iVzVNME1wQ2VoaUh6cmVTek5UY3prYzlkIj8+IDx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iIHg6eG1wdGs9IkFkb2JlIFhNUCBDb3JlIDUuMy1jMDExIDY2LjE0NTY2MSwgMjAxMi8wMi8wNi0xNDo1NjoyNyAgICAgICAgIj4gPHJkZjpSREYgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj4gPHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9IiIgeG1sbnM6eG1wPSJodHRwOi8vbnMuYWRvYmUuY29tL3hhcC8xLjAvIiB4bWxuczp4bXBNTT0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wL21tLyIgeG1sbnM6c3RSZWY9Imh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC9zVHlwZS9SZXNvdXJjZVJlZiMiIHhtcDpDcmVhdG9yVG9vbD0iQWRvYmUgUGhvdG9zaG9wIENTNiAoMTMuMCAyMDEyMDMwNS5tLjQxNSAyMDEyLzAzLzA1OjIxOjAwOjAwKSAgKE1hY2ludG9zaCkiIHhtcE1NOkluc3RhbmNlSUQ9InhtcC5paWQ6OUM2NjlDQjI4ODBGMTFFMTg1ODlEODNERDJBRjUwQTQiIHhtcE1NOkRvY3VtZW50SUQ9InhtcC5kaWQ6OUM2NjlDQjM4ODBGMTFFMTg1ODlEODNERDJBRjUwQTQiPiA8eG1wTU06RGVyaXZlZEZyb20gc3RSZWY6aW5zdGFuY2VJRD0ieG1wLmlpZDo5QzY2OUNCMDg4MEYxMUUxODU4OUQ4M0REMkFGNTBBNCIgc3RSZWY6ZG9jdW1lbnRJRD0ieG1wLmRpZDo5QzY2OUNCMTg4MEYxMUUxODU4OUQ4M0REMkFGNTBBNCIvPiA8L3JkZjpEZXNjcmlwdGlvbj4gPC9yZGY6UkRGPiA8L3g6eG1wbWV0YT4gPD94cGFja2V0IGVuZD0iciI/PsQhXeAAAABfSURBVHjaYvz//z8DJYCRUgMYQAbAMBQIAvEqkBQWXI6sHqwHiwG70TTBxGaiWwjCTGgOUgJiF1J8wMRAIUA34B4Q76HUBelAfJYSA0CuMIEaRP8wGIkGMA54bgQIMACAmkXJi0hKJQAAAABJRU5ErkJggg==) no-repeat 10px center;
  text-decoration: none; }

h1 tt, h1 code {
  font-size: inherit; }

h2 tt, h2 code {
  font-size: inherit; }

h3 tt, h3 code {
  font-size: inherit; }

h4 tt, h4 code {
  font-size: inherit; }

h5 tt, h5 code {
  font-size: inherit; }

h6 tt, h6 code {
  font-size: inherit; }

h1 {
  font-size: 28px;
  color: black; }

h2 {
  font-size: 24px;
  border-bottom: 1px solid #cccccc;
  color: black; }

h3 {
  font-size: 18px; }

h4 {
  font-size: 16px; }

h5 {
  font-size: 14px; }

h6 {
  color: #777777;
  font-size: 14px; }

p, blockquote, ul, ol, dl, li, table, pre {
  margin: 15px 0; }

hr {
  background: transparent url(data:image/png;base64,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) repeat-x 0 0;
  border: 0 none;
  color: #cccccc;
  height: 4px;
  padding: 0;
}

body > h2:first-child {
  margin-top: 0;
  padding-top: 0; }
body > h1:first-child {
  margin-top: 0;
  padding-top: 0; }
  body > h1:first-child + h2 {
    margin-top: 0;
    padding-top: 0; }
body > h3:first-child, body > h4:first-child, body > h5:first-child, body > h6:first-child {
  margin-top: 0;
  padding-top: 0; }

a:first-child h1, a:first-child h2, a:first-child h3, a:first-child h4, a:first-child h5, a:first-child h6 {
  margin-top: 0;
  padding-top: 0; }

h1 p, h2 p, h3 p, h4 p, h5 p, h6 p {
  margin-top: 0; }

li p.first {
  display: inline-block; }
li {
  margin: 0; }
ul, ol {
  padding-left: 30px; }

ul :first-child, ol :first-child {
  margin-top: 0; }

dl {
  padding: 0; }
  dl dt {
    font-size: 14px;
    font-weight: bold;
    font-style: italic;
    padding: 0;
    margin: 15px 0 5px; }
    dl dt:first-child {
      padding: 0; }
    dl dt > :first-child {
      margin-top: 0; }
    dl dt > :last-child {
      margin-bottom: 0; }
  dl dd {
    margin: 0 0 15px;
    padding: 0 15px; }
    dl dd > :first-child {
      margin-top: 0; }
    dl dd > :last-child {
      margin-bottom: 0; }

blockquote {
  border-left: 4px solid #dddddd;
  padding: 0 15px;
  color: #777777; }
  blockquote > :first-child {
    margin-top: 0; }
  blockquote > :last-child {
    margin-bottom: 0; }

table {
  padding: 0;border-collapse: collapse; }
  table tr {
    border-top: 1px solid #cccccc;
    background-color: white;
    margin: 0;
    padding: 0; }
    table tr:nth-child(2n) {
      background-color: #f8f8f8; }
    table tr th {
      font-weight: bold;
      border: 1px solid #cccccc;
      margin: 0;
      padding: 6px 13px; }
    table tr td {
      border: 1px solid #cccccc;
      margin: 0;
      padding: 6px 13px; }
    table tr th :first-child, table tr td :first-child {
      margin-top: 0; }
    table tr th :last-child, table tr td :last-child {
      margin-bottom: 0; }

img {
  max-width: 100%; }

span.frame {
  display: block;
  overflow: hidden; }
  span.frame > span {
    border: 1px solid #dddddd;
    display: block;
    float: left;
    overflow: hidden;
    margin: 13px 0 0;
    padding: 7px;
    width: auto; }
  span.frame span img {
    display: block;
    float: left; }
  span.frame span span {
    clear: both;
    color: #333333;
    display: block;
    padding: 5px 0 0; }
span.align-center {
  display: block;
  overflow: hidden;
  clear: both; }
  span.align-center > span {
    display: block;
    overflow: hidden;
    margin: 13px auto 0;
    text-align: center; }
  span.align-center span img {
    margin: 0 auto;
    text-align: center; }
span.align-right {
  display: block;
  overflow: hidden;
  clear: both; }
  span.align-right > span {
    display: block;
    overflow: hidden;
    margin: 13px 0 0;
    text-align: right; }
  span.align-right span img {
    margin: 0;
    text-align: right; }
span.float-left {
  display: block;
  margin-right: 13px;
  overflow: hidden;
  float: left; }
  span.float-left span {
    margin: 13px 0 0; }
span.float-right {
  display: block;
  margin-left: 13px;
  overflow: hidden;
  float: right; }
  span.float-right > span {
    display: block;
    overflow: hidden;
    margin: 13px auto 0;
    text-align: right; }

code, tt {
  margin: 0 2px;
  padding: 0 5px;
  white-space: nowrap;
  border: 1px solid #eaeaea;
  background-color: #f8f8f8;
  border-radius: 3px; }

pre code {
  margin: 0;
  padding: 0;
  white-space: pre;
  border: none;
  background: transparent; }

.highlight pre {
  background-color: #f8f8f8;
  border: 1px solid #cccccc;
  font-size: 13px;
  line-height: 19px;
  overflow: auto;
  padding: 6px 10px;
  border-radius: 3px; }

pre {
  background-color: #f8f8f8;
  border: 1px solid #cccccc;
  font-size: 13px;
  line-height: 19px;
  overflow: auto;
  padding: 6px 10px;
  border-radius: 3px; }
  pre code, pre tt {
    background-color: transparent;
    border: none; }

sup {
    font-size: 0.83em;
    vertical-align: super;
    line-height: 0;
}

kbd {
  display: inline-block;
  padding: 3px 5px;
  font-size: 11px;
  line-height: 10px;
  color: #555;
  vertical-align: middle;
  background-color: #fcfcfc;
  border: solid 1px #ccc;
  border-bottom-color: #bbb;
  border-radius: 3px;
  box-shadow: inset 0 -1px 0 #bbb
}

* {
	-webkit-print-color-adjust: exact;
}
@media screen and (min-width: 914px) {
    body {
        width: 854px;
        margin:0 auto;
    }
}
@media print {
	table, pre {
		page-break-inside: avoid;
	}
	pre {
		word-wrap: break-word;
	}
}
</style>


</head>

<body>

<h2 id="toc_0">Ornge Clinical Practice Guideline: Stroke</h2>

<p><i>Please refer to the Drug Monographs and References document for references listed in the CPGs</i>  </p>

<h2>Ischemic Stroke</h2>

<h3>Acute blood pressure management</h3>
<ul>
    <li>The ideal level of blood pressure to target in the hyperacute phase is unknown at this time</li>
    <li>Ischemic stroke patients eligible for thrombolytic therapy:</li>
    <ul>
        <li>Reduce Blood Pressure to a target of below 185/110mmHg</li>
        <li>Blood Pressure should be maintained below 180/105 mmHg for 24 h after alteplase administration</li>
    </ul>
    <li>Ischemic stroke patients eligible for EVT therapy:</li>
    <ul>
        <li>In patients for whom mechanical thrombectomy is planned and who have not received IV fibrinolytic therapy, it is reasonable to maintain BP ≤185/110 mmHg before the procedure</li>
        <li>In patients who have undergone mechanical thrombectomy, it is reasonable to maintain the BP at ≤180/105 mmHg during and for 24 hours after the procedure</li>
    </ul>
    <li>Ischemic stroke patients not eligible for thrombolytic therapy: Treatment of hypertension in the setting of acute ischemic stroke should not be routinely undertaken</li>
    <li>Extreme blood pressure elevation (i.e. systolic greater than 220 or diastolic greater than 120mmHg) should be treated to reduce the blood pressure by approximately 15%, and not more than 25%, over the first 24h, with further gradual reduction thereafter to targets for long-term secondary stroke prevention</li>
    <li>Avoidance of hypotension is important - attempt to maintain MAPs above 80</li>
</ul>

<h3>Blood glucose abnormalities</h3>
<ul>
    <li>All patients with suspected acute stroke should have their blood glucose concentration checked</li>
    <li>Hypoglycemia should be corrected immediately</li>
    <li>Treatment of hyperglycemia is reasonable as it has been associated with hemorrhagic transformation post IV alteplase thrombolysis</li>
</ul>

<h3>Additional management</h3>
<ul>
    <li>Supplemental oxygen should be provided for patients with oxygen saturation below 94%. Supplemental oxygen is not required for patients with normal oxygen saturation levels (94% or above)</li>
    <li>Temperature should be routinely monitored and treated if above 37.5°C</li>
    <li>All patients should be NPO unless a swallowing assessment has cleared the patient</li>
</ul>

<h2>Acute Ischemic Stroke Therapy</h2>

<h3>Patient selection</h3>
<ul>
    <li>Symptoms of disabling stroke - intravenous tPA (within 4.5h from stroke symptom onset) and interventional treatment with endovascular therapy (within a six-hour window from stroke symptom onset) in patients with an intracranial large vessel occlusion (LVO). Select patients with major disabling deficits and LVO may be candidates for EVT in the 6-24 h window.</li>
</ul>

<h3>Intravenous thrombolysis</h3>
<ul>
    <li>Administration of tPA 0.9mg/kg to a maximum of 90 mg total dose, with 10% (0·09mg/kg) given as an intravenous bolus over one-minute and the remaining 90% (0·81mg/kg) given as an intravenous infusion over 60 minutes</li>
    <li>Management of complications from tPA administration:</li>
    <ul>
        <li>There is insufficient evidence to support the routine use of fresh frozen plasma, prothrombin complex concentrates, or platelet transfusions for tPA-associated bleeding</li>
        <li>Angioedema and/or anaphylaxis should be managed as per the Ornge Anaphylaxis Medical Directive: Preference for Benadryl and steroids prior to administration of Epi in the setting of Post TPA patients especially if requiring ongoing hypertension management</li>
    </ul>
</ul>

<h3>Endovascular therapy</h3>
<ul>
    <li>Endovascular therapy is indicated in patients who have received intravenous tPA and those who are not eligible for intravenous tPA, or those select patients within 6-24 hours of presentation.</li>
    <li>Patients eligible for intravenous tPA as well as endovascular therapy should also be treated with intravenous tPA, which can be initiated while simultaneously planning and preparing the patient for transport for endovascular therapy</li>
</ul>

<h2>Acute Aspirin Therapy</h2>
<ul>
    <li>All acute stroke patients not already on an antiplatelet agent and not receiving tPA therapy should be given at least 160mg of acetylsalicylic acid (ASA) immediately as a one-time loading dose after brain imaging has excluded intracranial hemorrhage and after dysphagia screening has been performed and passed in consultation with the Receiving Stroke team</li>
    <li>In patients treated with tPA, acetylsalicylic acid (ASA) should be delayed until after the 24-hour postthrombolysis scan has excluded intracranial hemorrhage</li>
    <li>In pediatric patients, initial treatment with anticoagulation (heparin) or aspirin at established pediatric dosing should be considered and continued until cervical artery dissection and intracardiac thrombus is excluded. If neither is present, switch to acute aspirin therapy at dose of 1–5mg/kg</li>
    <li>In patients already on ASA prior to ischemic stroke or transient ischemic attack, clopidogrel may be considered as an alternative. If rapid action is required, then a loading dose of 300mg of clopidogrel could be considered, followed by a maintenance dose of 75mg once a day</li>
</ul>

<h2>Acute Intracerebral Hemorrhage</h2>

<h3>Blood pressure management</h3>
<ul>
    <li>A SBP target of less than 140–160 mm Hg for the first 24–48h post-ICH may be reasonable</li>
    <li>SBP lowering to a target of <140 mm Hg systolic does not worsen neurological outcomes (relative to 180 mm Hg systolic); however, clinical benefit has yet to be established</li>
    <li>Factors that may favor a lower target within this range (i.e. <140 mm HG) may include: presentation within 6 h of symptom onset; presenting SBP no greater than 220 mmHg; anticoagulation therapy; presence of neuroimaging markers of expansion and/or normal renal function</li>
    <li>Labetalol is recommended as a first-line treatment for acute blood pressure management if there are no contraindications</li>
</ul>

<h3>Blood glucose abnormalities</h3>
<ul>
    <li>All patients with suspected acute stroke should have their blood glucose concentration checked</li>
    <li>Hypoglycemia should be corrected immediately</li>
</ul>
<h3>Additional management</h3>
<ul>
    <li>Supplemental oxygen should be provided for patients with oxygen saturation below 94%. Supplemental oxygen is not required for patients with normal oxygen saturation levels (94% or above)</li>
    <li>Temperature should be routinely monitored and treated if above 37.5°C</li>
</ul>

<h3>Management of anticoagulation</h3>
<ul>
    <li>Patients on warfarin - PCC with Vitamin K 10 mg is preferred because the onset of action is fast, but fresh frozen plasma and vitamin K could be used as alternative if PCC is not available</li>
    <li>Antiplatelet agents (i.e. ASA, clopidogrel, dipyridamole/ASA) should be stopped immediately in patients who are routinely on these agents</li>
<li>Anticoagulation Reversal NOAC
<ul>
    <li>Dabigatran</li>
    <ul>
      <li>Idarucizumab 5 grams (2 x 2.5 vials) in 100 mL over 10 minutes by bolus infusion.</li> 
      <li>Compatible with NS.</li>
      <li>Risk: anaphylaxis.</li>
      <li>If Idarucizumab is unavailable consider four-factor PCC at a dose of 50 U/kg to a maximum dose of 3000 U</li>
    </ul>
    <li>Rivaroxaban/apiban</li>
      <ul>
        <li> aPCC/PCC-recommended by expert opinion.</li>
        <li> PCC 50 U/kg with a maximum dose of 3000 U flat dose.</li>
        <li> Repeat at 1 hour if ongoing bleeding.</li>
        <li>Unknown if you can use the INR to determine if there is unbound drug left after reversal</li>
      </ul>
  <li>Heparin/LMWH</li>
    <ul>
        <li>If the patient has received therapeutic low molecular weight heparin (LMWH) within the past 12h, consider administering protamine</li>
        <li>If the patient is receiving intravenous heparin infusion at the time of ICH, infusion should be immediately discontinued and consider administering protamine</li>
    </ul>
</ul>

</body>

</html>
